Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Donislecel Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Donislecel (Lantidra) Pancreatic Islet Cellular Therapy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical policy governs coverage and prior authorization for donislecel-JUJN administered under the medical benefit for adults with type 1 diabetes mellitus and severe hypoglycemia-related complications. It applies to initial, second, and third infusions and defines required clinical documentation, exclusions, and lifetime infusion limits.

    Policy Summary
    PayerMVP Health Care
    PolicyDonislecel (Lantidra) Pancreatic Islet Cellular Therapy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective Date04/01/2026
    Next Review DateN/A
    Key ActionObtain prior authorization for donislecel-JUJN when requested under the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J3590Medical-benefit prior authorization code
    18 to <65Coverage age range
    3Lifetime infusion maximum
    1 infusion/12 monthsInitial authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <50 mg/dLSevere hypoglycemia threshold
    <54 mg/dLReduced awareness threshold

    Coverage Criteria

    Initial Therapy

    Lantidra (donislecel) may be considered for coverage when ALL of the following criteria are met. Initial approval is for one infusion within 12 months.

    ALL of the following

    • The member is prescribed by or treated in consultation with an endocrinologist.
    • The member is between 18 years and less than 65 years of age.

      Safety and effectiveness have not been established in patients older than 65 years of age.

    • Confirmed diagnosis and qualifying complication

      • The member has a confirmed diagnosis of Type 1 diabetes for more than 5 years.
      • ONE of the following complications

        • Severe hypoglycemia

          • Documentation of at least one episode of severe hypoglycemia within the past 3 years.
          • The member required assistance from another person.
          • ANY of the following

            • Blood glucose level was less than 50 mg/dL.
            • The member recovered after administration of oral carbohydrate, intravenous glucose, or glucagon.
        • Reduced awareness of hypoglycemia, defined as absence of autonomic symptoms at capillary glucose levels less than 54 mg/dL.
    • Documentation that the member is unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia.
    • Documentation of intensive diabetes management and education.
    • Documentation that PCP and CMV prophylaxis will be provided, or provider attestation that they will be provided.
    • Documentation that the member is up to date with all vaccinations before initiating therapy.
    • Provider attestation that immunosuppression will continue permanently to prevent islet graft rejection.
    • Documentation of negative T-cell and B-cell crossmatch assay.

      Members with a positive T-cell and B-cell crossmatch between recipient serum and donor lymphocytes may reject the islet cells.

    • If applicable, documentation of previous donislecel infusion(s), including the date of each infusion.

    Second Infusion

    A second infusion may be considered when ALL of the following criteria are met in addition to updated clinical chart notes addressing all Initial Therapy criteria. Approval is for one infusion within 12 months.

    ALL of the following

    • The member does not achieve independence from exogenous insulin within one year of the prior infusion, or does not achieve or maintain independence within one year after losing independence from exogenous insulin after a previous infusion.
    • Claims history is subject to review.
    • The member has not experienced prior portal thrombosis, unless the thrombosis was limited to second- or third-order portal vein branches.

    Third Infusion

    A third infusion may be considered using the same criteria as the second infusion. Updated clinical chart notes must address all Initial Therapy criteria. Approval is for one infusion within 12 months.

    ALL of the following

    • The member does not achieve independence from exogenous insulin within one year of the prior infusion, or does not achieve or maintain independence within one year after losing independence from exogenous insulin after a previous infusion.
    • Claims history is subject to review.
    • The member has not experienced prior portal thrombosis, unless the thrombosis was limited to second- or third-order portal vein branches.

    Donislecel will not be covered when immunosuppression is contraindicated, when the member is pregnant, or when the member has renal failure or hepatic disease. Coverage is also excluded when liver function tests are outside the normal range.

    Donislecel is eligible for a maximum of 3 infusions per lifetime. More than 3 infusions are not covered.

    Donislecel is not covered for members who experienced prior portal thrombosis, unless the thrombosis was limited to second- or third-order portal vein branches.

    Coverage is excluded when the member's age, dose, frequency of dosing, and/or duration of therapy falls outside FDA-approved package labeling.

    Coding and Coverage Parameters

    Drugs Requiring Prior Authorization under the medical benefitHCPCS
    J3590donislecel-JUJN, IV suspension
    Severe hypoglycemia blood glucose
    Blood glucose threshold<50 mg/dL
    Assistance requirementThe member must require assistance from another person.
    Alternative recovery pathwayRecovery after oral carbohydrate, intravenous glucose, or glucagon administration also qualifies.
    Reduced hypoglycemia awareness
    Capillary glucose threshold<54 mg/dL
    Defining featureAbsence of autonomic symptoms at capillary glucose levels below 54 mg/dL.
    Coverage criterion

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Medical-benefit prior authorization is required before coverage of donislecel-JUJN intravenous suspension.

    • HCPCS J3590 — donislecel-JUJN, IV suspension
    Documentation Required

    Diabetes and Specialist Documentation

    The member must have Type 1 diabetes for more than 5 years and meet the age and specialist requirements. Clinical documentation must address the qualifying hypoglycemia history or reduced awareness, inability to approach target HbA1c because of repeated severe hypoglycemia, and intensive diabetes management and education.

    • Prescribed by or administered in consultation with an endocrinologist.
    • Member is 18 years of age through younger than 65 years; safety and effectiveness have not been established in patients older than 65.
    • Confirmed Type 1 diabetes diagnosis for more than 5 years.

    Therapy Background

    Donislecel is an allogeneic pancreatic islet cellular therapy made from pancreatic cells obtained from deceased donors. The infused pancreatic beta cells are intended to secrete insulin and help regulate blood glucose. The therapy is intended for adults with type 1 diabetes who cannot approach target HbA1c because of repeated severe hypoglycemia despite intensive diabetes management and education.

    Clinical Definitions

    Severe hypoglycemia
    Required assistanceThe member must require assistance from another person.
    Blood glucose pathwayBlood glucose level below 50 mg/dL
    Recovery pathwayRecovery after oral carbohydrate, intravenous glucose, or glucagon administration
    Reduced awareness of hypoglycemia
    DefinitionAbsence of autonomic symptoms at capillary glucose levels below 54 mg/dL.
    Capillary glucose threshold<54 mg/dL
    Clinical termReduced awareness of hypoglycemia

    Initial Therapy

    Initial Therapy Criteria

    Lantidra (donislecel) may be considered for coverage when ALL of the following are met.

    Initial donislecel therapy

    • Specialist and age: Prescribed by or in consultation with an endocrinologist; member is between 18 years and younger than 65 years of age18 years and <65 years
    • Type 1 diabetes and complication

      • Type 1 diabetes: Member has a confirmed diagnosis of type 1 diabetes for more than 5 years>5 years
      • ONE of

    Second or Third Infusion

    Second or Third Infusion Criteria

    A second or third infusion may be considered when ALL of the following are met, with updated clinical documentation addressing all initial criteria.

    Repeat infusion eligibility

    • ONE of

      • No initial insulin independence: Member does not achieve independence from exogenous insulin within one year of infusionWithin 1 year
      • Loss of insulin independence: Member loses independence from exogenous insulin within one year after a previous infusionWithin 1 year after loss of insulin independence

    Infusion Quantity Limits

    Initial donislecel quantity limit
    Initial quantity limitOne infusion
    Time periodWithin 12 months
    Authorization contextInitial approval for the first infusion
    Lifetime donislecel quantity limit
    Lifetime quantity limitThree infusions total
    Lifetime basisThe limit applies over the member’s lifetime.
    Coverage restrictionMore than 3 infusions per lifetime is not covered.
    Policy Summary
    PayerMVP Health Care
    PolicyDonislecel (Lantidra) Pancreatic Islet Cellular Therapy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective Date04/01/2026
    Next Review DateN/A
    Key ActionObtain prior authorization for donislecel-JUJN when requested under the medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Actions and DocumentationTherapy BackgroundClinical DefinitionsInitial TherapySecond or Third InfusionInfusion Quantity Limits
    Reduced awareness of hypoglycemia is an alternative complication criterion to documented severe hypoglycemia.
    Type 1 diabetes duration
    Required durationMore than 5 years
    DiagnosisConfirmed type 1 diabetes mellitus
    Related coverage requirementThe member must also have documented severe hypoglycemia within the past 3 years or reduced awareness of hypoglycemia.
    Member age range
    Minimum age18 years
    Maximum ageYounger than 65 years
    Age criterionThe member must be between 18 years and younger than 65 years of age.
    Initial infusion authorization
    Initial quantity1 infusion
    Authorization periodWithin 12 months
    Applies toInitial approval for the first infusion
    Maximum lifetime infusions
    Lifetime maximum3 infusions total
    Excess quantityMore than 3 infusions per lifetime is not covered.
    Repeat infusionsA second or third infusion may be considered under the applicable continuation criteria.
  1. Document at least one qualifying complication: severe hypoglycemia in the past 3 years or reduced awareness of hypoglycemia.
  2. Document inability to approach target HbA1c because of current repeated episodes of severe hypoglycemia.
  3. Document intensive diabetes management and education.
  4. Documentation Required

    Hypoglycemia Documentation

    Document the qualifying hypoglycemia event or reduced awareness. Severe hypoglycemia requires assistance from another person and either the specified glucose result or documented recovery after rescue treatment.

    • At least one episode of severe hypoglycemia within the past 3 years.
    • The member required assistance from another person.
    • Blood glucose was <50 mg/dL, or the member recovered after oral carbohydrate, intravenous glucose, or glucagon administration.
    • Alternatively, reduced awareness is documented as absence of autonomic symptoms at capillary glucose levels <54 mg/dL.
    Documentation Required

    Prophylaxis, Vaccination, and Immunosuppression

    Before therapy, document the required prophylaxis, vaccination status, and the provider's commitment to permanent immunosuppression to prevent islet graft rejection.

    • Document PCP and CMV prophylaxis, or provide provider attestation that they will be provided.
    • Document that the member is up to date with all vaccinations before initiating therapy.
    • Provide provider attestation that immunosuppression will continue permanently to prevent islet graft rejection.
    Documentation Required

    Crossmatch and Prior Infusion Records

    Submit compatible immunologic testing and any applicable prior infusion records with the request.

    • Document negative T-cell and B-cell crossmatch assay results; positive T-cell and B-cell crossmatch results may lead to rejection of the islet cells.
    • If applicable, document each previous donislecel infusion and its date.
    Documentation Required

    Repeat-Infusion Documentation

    Requests for a second or third infusion require updated clinical chart notes addressing all initial criteria and documentation that the member did not achieve or maintain independence from exogenous insulin. Claims history is subject to review.

    • A second infusion may be considered if the member does not achieve independence from exogenous insulin within 1 year of the prior infusion, or within 1 year after losing independence following a previous infusion.
    • A third infusion uses the same criteria as the second infusion.
    • Approval for each second or third infusion is limited to one infusion within 12 months.
    • Submit updated clinical chart notes addressing all applicable initial criteria.
    • Claims history is subject to review.
    Denial Risk

    Exclusionary Conditions

    Coverage is denied when an exclusionary clinical condition or labeling limitation applies.

    • Immunosuppression is contraindicated.
    • Age, dose, frequency of dosing, or duration of therapy is outside FDA-approved package labeling.
    • The member is pregnant.
    • The member has renal failure.
    • The member has hepatic disease or liver function tests outside the normal range.
    • More than 3 infusions would be provided over the member's lifetime.
    Billing Rule

    Infusion and Portal Thrombosis Limits

    Donislecel is limited to 3 infusions over a lifetime. Initial approval is for one infusion within 12 months, and repeat approvals are separately limited to one infusion within 12 months. Prior portal thrombosis generally excludes coverage.

    • Maximum: 3 donislecel infusions per lifetime.
    • Initial approval: 1 infusion within 12 months.
    • Second- and third-infusion approvals: 1 infusion within 12 months when applicable criteria are met.
    • Not covered for members with prior portal thrombosis unless the thrombosis was limited to second- or third-order portal vein branches.
    Documentation Required

    Initial Clinical Criteria

    Initial coverage requires all applicable diabetes, age, hypoglycemia, management, prophylaxis, vaccination, immunosuppression, and testing requirements to be documented before therapy.

    • Prescribed by or administered in consultation with an endocrinologist; member is 18 through younger than 65 years; and confirmed Type 1 diabetes has been present for more than 5 years.
    • At least one qualifying complication is documented: severe hypoglycemia within the past 3 years, as defined by assistance from another person plus glucose <50 mg/dL or recovery after oral carbohydrate, intravenous glucose, or glucagon; or reduced awareness of hypoglycemia, defined as absence of autonomic symptoms at capillary glucose <54 mg/dL.
    • The member is unable to approach target HbA1c because of current repeated severe hypoglycemia, and intensive diabetes management and education are documented.
    • PCP and CMV prophylaxis are documented or attested to; vaccinations are current before therapy; and permanent immunosuppression is attested to.
    • Negative T-cell and B-cell crossmatch results are documented, along with prior donislecel infusion dates when applicable.
  5. Severe hypoglycemia: At least one episode of severe hypoglycemia in the past 3 years required assistance from another person and involved either a blood glucose level below 50 mg/dL or recovery after oral carbohydrate, intravenous glucose, or glucagon administration<50 mg/dL
  6. Reduced awareness of hypoglycemia: Absence of autonomic symptoms at capillary glucose levels below 54 mg/dL<54 mg/dL
  7. Clinical need and preparation

    • Glycemic management: Member is unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia
    • Diabetes management: Intensive diabetes management and education is documented
    • Prophylaxis: PCP and CMV prophylaxis is documented or the provider attests that prophylaxis will be provided
    • Vaccinations: Member is up to date with all vaccinations before initiating therapy
    • Immunosuppression: Provider attests that immunosuppression will continue permanently to prevent islet graft rejection
    • Crossmatch: T-cell and B-cell crossmatch assay is negativeNegative T-cell and B-cell crossmatch
    • Prior infusion history: When applicable, documentation includes the date of each previous donislecel infusion
  8. Updated initial-therapy documentation: Updated clinical chart notes address all applicable initial criteria, including endocrinologist involvement, age, type 1 diabetes duration, severe hypoglycemia or reduced awareness, inability to approach target HbA1c, intensive diabetes management and education, prophylaxis, current vaccinations, permanent immunosuppression, negative T-cell and B-cell crossmatch, and prior infusion dates when applicable
  9. Claims review: Claims history is subject to review
  10. Portal thrombosis limitation: Member has no prior portal thrombosis, unless the thrombosis was limited to second- or third-order portal vein branches